139 related articles for article (PubMed ID: 38105274)
21. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
22. Does semantic memory impairment in amnestic MCI with hippocampal atrophy conform to a distinctive pattern of progression?
Quaranta D; Vita MG; Spinelli P; Scaricamazza E; Castelli D; Lacidogna G; Piccininni C; Rossini PM; Gainotti G; Marra C
Curr Alzheimer Res; 2014 May; 11(4):399-407. PubMed ID: 24635841
[TBL] [Abstract][Full Text] [Related]
23. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of 11C-Pittsburgh compound-B positron emission tomography in addition to magnetic resonance imaging and single-photon emission computed tomography on diagnosis of mild cognitive impairment to Alzheimer's disease.
Kitajima K; Abe K; Takeda M; Yoshikawa H; Ohigashi M; Osugi K; Koyama H; Yamakado K
Medicine (Baltimore); 2021 Jan; 100(3):e23969. PubMed ID: 33545981
[TBL] [Abstract][Full Text] [Related]
25. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
[TBL] [Abstract][Full Text] [Related]
26. Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment.
Thurfjell L; Lötjönen J; Lundqvist R; Koikkalainen J; Soininen H; Waldemar G; Brooks DJ; Vandenberghe R
Neurodegener Dis; 2012; 10(1-4):246-9. PubMed ID: 22301718
[TBL] [Abstract][Full Text] [Related]
27. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia.
Rabinovici GD; Gatsonis C; Apgar C; Chaudhary K; Gareen I; Hanna L; Hendrix J; Hillner BE; Olson C; Lesman-Segev OH; Romanoff J; Siegel BA; Whitmer RA; Carrillo MC
JAMA; 2019 Apr; 321(13):1286-1294. PubMed ID: 30938796
[TBL] [Abstract][Full Text] [Related]
28. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: a multisite observational cohort study.
Goukasian N; Hwang KS; Romero T; Grotts J; Do TM; Groh JR; Bateman DR; Apostolova LG
BMJ Open; 2019 Dec; 9(12):e031947. PubMed ID: 31857304
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.
Ossenkoppele R; Smith R; Mattsson-Carlgren N; Groot C; Leuzy A; Strandberg O; Palmqvist S; Olsson T; Jögi J; Stormrud E; Cho H; Ryu YH; Choi JY; Boxer AL; Gorno-Tempini ML; Miller BL; Soleimani-Meigooni D; Iaccarino L; La Joie R; Baker S; Borroni E; Klein G; Pontecorvo MJ; Devous MD; Jagust WJ; Lyoo CH; Rabinovici GD; Hansson O
JAMA Neurol; 2021 Aug; 78(8):961-971. PubMed ID: 34180956
[TBL] [Abstract][Full Text] [Related]
30. [Neuropathology of mild cognitive impairment].
Takao M
Rinsho Shinkeigaku; 2012; 52(11):851-4. PubMed ID: 23196441
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
[TBL] [Abstract][Full Text] [Related]
32. Do cerebral white matter lesions influence the rate of progression from mild cognitive impairment to dementia?
Devine ME; Fonseca JA; Walker Z
Int Psychogeriatr; 2013 Jan; 25(1):120-7. PubMed ID: 22874528
[TBL] [Abstract][Full Text] [Related]
33. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
34. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
35. Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.
Choi HJ; Seo EH; Yi D; Sohn BK; Choe YM; Byun MS; Lee JM; Woo JI; Lee DY
Am J Geriatr Psychiatry; 2016 Feb; 24(2):144-53. PubMed ID: 26238231
[TBL] [Abstract][Full Text] [Related]
36. Neuroanatomical correlates of awareness of illness in patients with amnestic mild cognitive impairment who will or will not convert to Alzheimer's disease.
Spalletta G; Piras F; Piras F; Sancesario G; Iorio M; Fratangeli C; Cacciari C; Caltagirone C; Orfei MD
Cortex; 2014 Dec; 61():183-95. PubMed ID: 25481475
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of mild cognitive impairment tending to convert into Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a memory clinic.
Kondo D; Ota K; Kasanuki K; Fujishiro H; Chiba Y; Murayama N; Sato K; Hirayasu Y; Arai H; Iseki E
J Neurol Sci; 2016 Oct; 369():102-108. PubMed ID: 27653873
[TBL] [Abstract][Full Text] [Related]
38. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
[TBL] [Abstract][Full Text] [Related]
39. Changes in LASSI-L performance over time among older adults with amnestic MCI and amyloid positivity: A preliminary study.
Kitaigorodsky M; Curiel Cid RE; Crocco E; Gorman KL; González-Jiménez CJ; Greig-Custo M; Barker WW; Duara R; Loewenstein DA
J Psychiatr Res; 2021 Nov; 143():98-105. PubMed ID: 34464879
[TBL] [Abstract][Full Text] [Related]
40. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
